Prevalence and association of medication nonadherence with major adverse cardiovascular events in patients with myocardial infarction

Yunfeng Hou, MDa, Yifeng Yue, MDb, Meiling Zhao, MDc, Shumin Jiang, MDa,∗

Abstract
Current study was to evaluate the prevalence of guideline recommended medications adherence in myocardial infarction (MI) patients postpercutaneous coronary intervention (PCI) and the association of medication nonadherence and major adverse cardiovascular events (MACEs).

MI patients who underwent PCI in the last 12 months were enrolled. Demographic and clinical characteristics were collected and guideline recommended medications were evaluated. Patients were divided into with and without MACEs groups.

Compared to patients without MACEs, those with MACEs were older (54.8 ± 16.4 vs 51.1 ± 15.2 years), more likely to be smoker (40.2% vs 31.9%), have higher body mass index (BMI; 25.0 ± 6.1 vs 23.8 ± 5.7 kg/m²), diabetes (47.5% vs 37.8%), ischemic stroke (34.4% vs 25.6%), and estimated lower glomerular filtration rate (85.4 ± 9.6 vs 92.6 ± 10.7 mL/minute/1.73 m²). Patients with MACEs were also more likely to present with ST-elevation MI (STEMI; 54.1% vs 48.4%) and to undergo urgent PCI (62.3% vs 56.3%). Furthermore, patients with MACEs were less likely to adhere to dual antiplatelet therapy (77.9% vs 85.9%), renin–angiotensin system inhibitor (62.3% vs 69.7%), and beta-blocker (69.7% vs 72.8%) treatment. In unadjusted model, medication nonadherence was associated with 2-fold higher odds of MACEs. After adjustment for demographics, risk factors, comorbidities, and peri-PCI characteristics, medications nonadherence remained independently associated with MACEs, with odds ratio of 1.40 (95% confidence interval: 1.29–1.87).

Medication adherence rate among MI patients post-PCI is suboptimal in China, which is independently associated with MACEs.

Abbreviations: ACEI/ARB = angiotensin converting enzyme inhibitor or angiotensin receptor blocker, DAPT = dual antiplatelet therapy, MACE = major adverse cardiovascular event, MI = myocardial infarction, PCI = percutaneous coronary intervention, STEMI = ST-elevation MI, TVR = targeted vessel revascularization.

Keywords: medications adherence, myocardial infarction, percutaneous coronary intervention

1. Introduction

Myocardial infarction (MI) is one of the leading causes of morbidity and mortality around the world.[1–5] In the past decades, with the advancement of percutaneous coronary intervention (PCI), numerous patients survive MI through undergoing urgent and successful coronary artery revascularization.[6–11] However, a substantial proportion of MI patients would experience recurrent MI or develop congestive heart failure after discharge.[12–17] Therefore, how to improve long-term prognosis of these populations is clinically relevant and important.

In accordance to the guideline recommendations,[13] MI patients post-PCI should take at least 12 months dual antiplatelet therapy (DAPT), lifelong statins, angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACEI/ARB), and beta-blocker. Nevertheless, prior observational studies show that a substantial proportion of MI patients did not adhere to the guideline recommended medications therapy,[14–17] and these patients had poorer prognosis than those who adhered to medications therapy.[18–20]

Notably, most of prior studies were conducted in Caucasian populations and the data on Chinese MI patients is scare. Herein, we aimed to evaluate the prevalence of guideline recommended medications adherence in MI patients post-PCI in our hospital. In addition, we evaluate the association of nonadherence to guideline recommended medications and major adverse cardiovascular events (MACEs). Hopefully, results from our current study can provide clues to improve medications adherence and improve prognosis of MI patients after PCI therapy in the future.

2. Methods

2.1. Participants’ enrollment

The protocol of current study was approved by the Research Ethic Committee of Qianfoshan Hospital of Shandong University, and informed consent was obtained from participants before
enrollment. The inclusion criteria were as follows: prior PCI was
underwent at our hospital, prior PCI was performed within the
last 12 months due to MI, and patients were follow-up at our
hospital with intact information of follow-up medications
prescription; and the exclusion criteria were as follows: patients
underwent PCI due to other reasons (eg, stable angina), patients
had contraindications to guideline recommended medications
(eg, angioedema due to ACEI/ARB), or patients underwent PCI
more than 12 months ago who was reasonable to discontinue
DAPT.

2.2. Demographic, risk factors, and comorbidities
collection
Demographics included age and sex, and body mass index (BMI)
was calculated by weight in kilogram divided by height in
squared meters. Risk factors included history of smoking,
hypertension, dyslipidemia, and diabetes. Comorbidities includ-
ed history of ischemic stroke, peripheral arterial disease, and
chronic kidney disease. All these data were collected from
electronic medical record.

2.3. Laboratory data
Fasting venous blood was drawn for evaluation of serum levels of
fasting plasma glucose, low-density lipoprotein-cholesterol,
alanine aminotransferase, and creatinine. Serum creatinine level
was used to calculate estimated glomerular filtration rate based
on the MDRD formula.[21]

2.4. Characteristics of peri-PCI
Characteristics of peri-PCI including presentation as ST-elevation
MI (STEMI) or non-STEMI, underwent urgent or elective PCI,
peri-PCI antiplatelet drug loading, and the number and type of
stent implanted were documented from electronic medical record.
In specific, all these peri-PCI characteristics were collected after
patients were enrolled in our current study.

2.5. Medications adherence evaluation
Medications adherence evaluation was based on the outpatient
medication prescription system and inpatient medical record
system, which allowed us to evaluate the prescription, refill, and
change of medications. Medication adherence was evaluated by 2
independent investigators, and patients who did not get
medications refill longer than 7 days were considered as
medication nonadherence.

2.6. Assessment of MACEs
MACEs in our current study was defined as composite of angina
symptoms, MI, targeted vessel revascularization (TVR), and new
onset of congestive heart failure. All the outcomes were
documented and adjudicated by 2 independent cardiologists.

2.7. Statistical analysis
Continuous variables were presented as mean ± SD and com-
pared by Student t test; categorical variables were presented by
proportion and number and compared by the chi-square or
Fisher exact test for categorical variables. Logistic regression
analyses were performed to evaluate the associations of
medications nonadherence and MACEs. Statistical analyses were
computed using SPSS 19.0 (SPSS Inc, Chicago, IL). All statistical
tests were 2-sided and considered statistically significant when
P < .05.

3. Results
3.1. Participants’ enrollment
A total of 648 MI patients were encountered during January of
2018 to December of 2018 at the outpatient department of our
hospital. After exclusion of 206 patients, 442 patients were
enrolled and divided into with (n = 122) and without (n = 320)
MACEs groups (Fig. 1). Among the 122 patients with MACEs,
45 (36.9%), 17 (13.9%), 6 (4.9%), and 34 (44.3%) had
experienced angina, MI, TVR, and congestive heart failure post-
PCI, respectively.

3.2. Baseline characteristics comparisons
Baseline characteristics were compared and as presented in
Table 1, compared to patients without MACEs, those with
MACEs were older (54.8 ± 16.4 vs 51.1 ± 15.2 years), more likely
to be smoker (40.2% vs 31.9%), have higher BMI (25.0 ± 6.1 vs
23.8 ± 5.7 kg/m²), diabetes (47.5% vs 37.8%), ischemic stroke
(34.4% vs 25.6%), and lower estimated glomerular filtration rate
(85.4 ± 9.6 vs 92.6 ± 10.7 mL/minute/1.73 m²). In addition,
patients with MACEs were also more likely to present with
STEMI (54.1% vs 48.4%) and to undergo urgent PCI (62.3% vs
56.3%).

3.3. Guideline recommended medications adherence
comparisons
At the time of participant’s enrollment, adherence to guideline
recommended medications was evaluated. As presented in
Figure 2, the prevalence of overall adherence to guideline
recommended medications in our study’s population was 83.7%
(DAPT), 67.6% (ACEI/ARB), 81.8% (statins), and 71.9% (beta-
blocker), respectively.

Compared to those without MACEs, patients with MACEs
were less likely to adhere to DAPT (77.9% vs 85.9%), ACEI/ARB
(62.3% vs 69.7%), and beta-blocker (69.7% vs 72.8%) treatment.

3.4. Associations of medications nonadherence and
MACEs
Logistic regression analysis was conducted to evaluate the
association of medication nonadherence and MACEs. As
presented in Table 2, in the unadjusted model, medication
nonadherence was associated with 2-fold higher odds of MACEs.
After adjustment for demographics, the associations were
attenuated slightly. Although adjustment for risk factors, the
odds were attenuated by 24% (from 1.96 to 1.72). In the model 3,
adjustment for comorbidities also attenuated the odds slightly.
However, with further adjustment for peri-PCI characteristics,
the odds were attenuated by 25% (from 1.96 to 1.72). These
findings together indicated that medications nonadherence was
independently associated with MACEs in MI patients post-PCI
therapy.
4. Discussion

To our knowledge, the current analysis should be the first few studies to evaluate the prevalence of guideline recommended medications adherence in Chinese MI patients post-PCI therapy. Our results show that the prevalence of medications adherence was suboptimal. Compared to those without MACEs, patients with MACEs are more likely to nonadherence to guideline recommended medications therapy. In addition, after adjustment for covariates, medications nonadherence remains independently associated with MACEs.

Notably, DAPT, ACEI/ARB, statins, and beta-blocker are standard of care for MI patients post-PCI therapy. Prior randomized controlled trials have demonstrated that compared to placebo, these medications can reduce cardiovascular events and improve patients’ prognosis.[22–24] Nevertheless, numerous studies have shown that a substantial proportion of patients did not adhere to guideline recommended medications therapy and these patients were at higher risk of experiencing angina, recurrent MI, in-stent restenosis, and congestive heart failure.[25–29] These findings together demonstrate that how to improve patients’ adherence to guideline recommended medications therapy is a good opportunity to reduce health and economic burden in China.[22]

In the past decades, the incidence of MI in China increased dramatically and PCI was also routinely applied to MI patients. However, the data on guideline recommended medications adherence post-PCI therapy was scare. Our current study for the first time showed that at the first 12 months post-PCI therapy, the overall adherence to DAPT, ACEI/ARB, statins, and beta-blocker therapy was 83.7%, 67.6%, 81.8%, and 71.9%, respectively. Since we had excluded those who were contraindicative to these medications treatment, therefore, theoretically, all these patients should be necessary to take the guideline recommended medications. However, it might be possible that after PCI, some patients developed medications related side effects such as bleeding events, hypotension, or bradycardia, which resulted in premature discontinuation of these medications.

Regardless of the reason for the premature discontinuation of guideline recommended medications, our results support the notion that among MI patients post-PCI therapy, nonadherence to guideline recommended medications therapy was associated with MACEs. Our findings were consistent with prior reports. For example, Moalem et al[24] reported that approximately 1 in 10 patients disrupts DAPT due to nonadherence, which resulted

---

Table 1

Baseline characteristics comparisons.

| Variables                        | Without event (n = 320) | With event (n = 122) |
|----------------------------------|------------------------|---------------------|
| Age, y                           | 51.1 ± 15.2            | 54.8 ± 16.4*        |
| Male, n, %                       | 178 (56.6)             | 70 (57.4)           |
| BMI, kg/m²                       | 23.8 ± 5.7             | 25.0 ± 6.1*         |
| Smoking, n, %                    | 102 (31.9)             | 49 (40.2)           |
| Dyslipidemia, n, %               | 234 (73.1)             | 89 (73.0)           |
| Diabetes mellitus, n, %          | 121 (37.8)             | 58 (47.5)*          |
| Hypertension, n, %               | 176 (55)               | 70 (57.4)           |
| CKD, n, %                        | 72 (22.5)              | 26 (21.3)           |
| PAD, n, %                        | 84 (26.3)              | 33 (27)             |
| Ischemic stroke, n, %            | 82 (25.6)              | 42 (34.4)*          |
| FPG, mg/dL                       | 95.7 ± 14.4            | 96.2 ± 14.8         |
| LDL-C, mmol/L                    | 5.0 ± 0.9              | 5.1 ± 1.0           |
| ALT, U/L                         | 30.1 ± 13.1            | 28.8 ± 14.2         |
| Creatinine, μmol/L               | 72.4 ± 21.6            | 73.8 ± 20.4         |
| EGR, mL/minute/1.73 m²           | 80.6 ± 22.7            | 77.4 ± 20.5*        |
| STEMI presentation, n, %         | 155 (48.4)             | 66 (54.1)*          |
| Urgent PCI, n, %                 | 180 (56.3)             | 76 (62.3)*          |
| Antiplatelet drug loading, n, %  | 246 (76.9)             | 92 (75.4)           |
| Number of stents                 | 1.8 ± 0.6              | 1.9 ± 0.6           |
| Drug-eluting stents, n, %        | 268 (83.8)             | 102 (83.6)          |

ALT = alanine aminotransferase, BMI = body mass index, CKD = chronic kidney disease, eGFR = estimated glomerular filtration rate, FPG = fasting plasma glucose, LDL-C = low-density lipoprotein-cholesterol, PAD = peripheral arterial disease, PCI = percutaneous coronary intervention, STEMI = ST-segment elevation myocardial infarction.

* P < .05 versus without outcome group.
in higher risk for ischemic events. Bangalore et al.\(^{[27]}\) reported that among MI patients, maintenance on beta-blocker treatment was associated with reduced risk of recurrent MI and angina symptoms. Kalsekar et al.\(^{[28]}\) reported that among MI patients, those who adhered to ACEI treatment was less likely to develop congestive heart failure than those who did not adhere to ACEI treatment. In our current analysis, through stepwise adjustment for potential covariates including demographics, risk factors, comorbidities, and peri-PCI characteristics, medication nonadherence remained independently associated with MACEs. In current study, we defined MACEs as composite of angina symptoms, MI, TVR, and congestive heart failure because these events were strongly associated with guideline recommended medications discontinuation. In specific, among the 122 patients with MACEs, 45 (36.9%), 17 (13.9%), 6 (4.9%), and 54 (44.3%) had experienced angina, MI, TVR, and congestive heart failure post-PCI, respectively. We observed that compared to those without MACEs, the rate of nonadherence to DAPT, ACEI/ARB, and beta-blocker was significantly higher in patients with MACEs. These findings collectively demonstrate that nonadherence to guideline recommended medications therapy is common in Chinese PCI patients, and concerted efforts are needed to improve patients’ adherence to guideline recommended medications therapy.

There are some limitations of our current study. First of all, this is an observational study and findings from our study cannot establish causal relationship between medications nonadherence and MACEs. However, our study provided insight into the association of medication nonadherence and MACEs in Chinese PCI patients. Second, despite we have extensively adjusted for potential covariates, unmeasured and undetected covariates remained possible to influence the association between medications nonadherence and MACEs. Last but not the least, this is a single center study and findings from our current study may not be able to extrapolate to other population groups. Further studies in China are needed to corroborate our findings.

5. Conclusion
In summary, our current study shows that guideline recommended medications adherence rate among MI patients post-PCI is suboptimal in China and medication nonadherence is independently associated with MACEs. Further studies are warranted to investigate how to improve medications adherence rate in China.

Acknowledgments
The authors thank the help of Dr James K Wang provided to authors.

Author contributions
Conceptualization: Yunfeng Hou, Shumin Jiang.
Data curation: Yunfeng Hou, Yifeng Yue, Meiling Zhao.
Formal analysis: Yifeng Yue.
Funding acquisition: Yunfeng Hou, Shumin Jiang.
Methodology: Meiling Zhao.
Resources: Yifeng Yue, Meiling Zhao.
Supervision: Meiling Zhao, Shumin Jiang.
Validation: Yifeng Yue, Meiling Zhao, Shumin Jiang.
Writing – original draft: Yunfeng Hou.
Writing – review & editing: Shumin Jiang.

Table 2
Associations of medication nonadherence and composite cardio-vascular events.

| Independent variables | Odds ratio | 95% Confidence interval |
|-----------------------|------------|------------------------|
| Unadjusted            | 2.01       | 1.87–2.74              |
| Model 1               | 1.96       | 1.79–2.63              |
| Model 2               | 1.72       | 1.60–2.27              |
| Model 3               | 1.65       | 1.51–2.06              |
| Model 4               | 1.40       | 1.29–1.67              |

Model 1 = adjusted for age, male gender, and body mass index; model 2 = further adjusted for smoking, dyslipidemia, hypertension, diabetes, and glomerular filtration rate; model 3 = further adjusted for ischemic stroke and peripheral arterial disease; and model 4 = further adjusted for presentation as STEMI and underwent urgent PCI. PCI = percutaneous coronary intervention, STEMI = ST-segment elevation myocardial infarction.

Figure 2. Medications adherence evaluation. ACEI/ARB = angiotensin converting-enzyme inhibitor/angiotensin receptor blocker, DAPT = dual antiplatelet therapy.
References

[1] Li J, Li X, Wang Q, et al. ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective analysis of hospital data. Lancet 2015;385:441–51.

[2] Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2095–128.

[3] Joshi P, Islam S, Pais P, et al. Risk factors for early myocardial infarction with and without acute coronary syndrome: a systematic review and meta-analysis. Atherosclerosis 2016;254:215–27.

[4] Chiarito M, Sardella G, Colombo A, et al. Safety and efficacy of long-term treatment with statins for coronary heart disease: a randomized clinical trial. JAMA 2007;297:286–94.

[5] Huber CA, Meyer MR, Steffel J, et al. Post-myocardial infarction (MI) care: medication adherence for secondary prevention after MI in a large real-world population. Clin Ther 2019;41:107–17.

[6]娟娟 D, Bartos JA, Aufderheide TP, et al. The evolving role of the cardiac catheterization laboratory in the management of patients with out-of-hospital cardiac arrest: a scientific statement from the American Heart Association. Circulation 2019;139:e530–27.

[7] Sadowski M, Gutowski W, Raczyński G, et al. Acute myocardial infarction due to left main coronary artery disease in men and women: does ST-segment elevation matter. Arch Med Sci 2015;11:1197–204.

[8] Yannopoulos D, Bartos JA, Aufderheide TP, et al. The evolving role of the cardiac catheterization laboratory in the management of patients with out-of-hospital cardiac arrest: a scientific statement from the American Heart Association. Circulation 2019;139:e530–52.

[9] Cai A, Li X, Zhong Q, et al. Associations of high HDL cholesterol level with all-cause mortality in patients with heart failure complicating coronary heart disease. Medicine (Baltimore) 2016;95:e3974.

[10] Vardy J, Anwerp M, Zborak M, et al. 2013 ACC/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128:e240–327.

[11] Al-Zaibak H, Elastafi AA, Ulla A, et al. Acute heart failure with and without acute coronary syndrome: clinical correlates and prognostic impact (from the HEARTS registry). BMC Cardiovasc Disord 2016;16:98.

[12] Lu Y, Cheng Z, Zhao Y, et al. Efficacy and safety of long-term treatment with statins for coronary heart disease: a Bayesian network meta-analysis. Athero-sclesor 2016;254:215–27.

[13] Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction. Circulation 2018;138:e618–51.

[14] Hirsh BJ, Smolower NR, Rosenson RS, et al. Utilization of and adherence to guideline-recommended lipid-lowering therapy after acute coronary syndrome: opportunities for improvement. J Am Coll Cardiol 2015;66:184–92.

[15] Mousatou K, Babin B, Chourdikar J, et al. Incidence, predictors, and outcomes of DAPT disruption due to non-compliance vs. bleeding after PCI: insights from the PARIS Registry. Clin Res Cardiol 2019;108:643–50.

[16] Bangalore S, Makani H, Radford M, et al. Clinical outcomes with β-blockers for myocardial infarction: a meta-analysis of randomized trials. Am J Med 2014;127:939–53.

[17] Kalsekar I, Koehler J, Mulvaney J. Impact of ACE inhibitors on mortality and morbidity in patients with AML does tissue selectivity matter. Value Health 2011;14:384–91.

[18] Hickson RP, Robinson JG, Annis IE, et al. Changes in statin adherence following an acute myocardial infarction among older adults: patient predictors and the association with follow-up with primary care providers and/or cardiologists. J Am Heart Assoc 2017;6: pii: e007106.